

3. Ouyang P, Gerstenblith G, Furman GR: Coronary artery disease: Frequency and significance of early postoperative silent myocardial ischemia in patients having peripheral vascular surgery. *Am J Cardiol* 64:1113-1116, 1989
4. Pasternack PF, Grossi EA, Bauman FG: The value of silent myocardial ischemia monitoring in the prediction of perioperative myocardial infarction in patients undergoing peripheral vascular surgery. *J Vasc Surg* 10:617-625, 1989
5. Lee DD, Kimura S, DeQuattro V: Noradrenergic activity and silent ischemia in hypertensive patients with stable angina: Effect of metoprolol. *Lancet* 1:403-406, 1989
6. Vanhoutte PM, Shimokawa H: Endothelium-derived relaxing factor and coronary vasospasm. *Circulation* 80:1-9, 1989
7. McDaniel MD, Pearce WH, Yao JST: Sequential changes in coagulation and platelet function following femorotibial bypass. *J Vasc Surg* 1:261-268, 1984
8. Tuman KJ, McCarthy RJ, March RJ, DeLaria GA, Patel RV, Ivankovich AD: Effects of epidural anesthesia and analgesia on coagulation and outcome after major vascular surgery. *Anesth Analg* 73:696-704, 1991
9. Beattie WS, Buckley DN, Forrest JB: Reduction of significant cardiac morbidity by epidural morphine in noncardiac surgery (abstract). *ANESTHESIOLOGY* 73:A71, 1990
10. Pasternack PF, Grossi EA, Bauman FG: Beta blockade to decrease silent myocardial ischemia during peripheral vascular surgery. *Am J Surg* 158:113-116, 1989
11. Seitelberger R, Zwolfer W, Binder TM: Infusion of nifedipine after coronary bypass grafting decreases the incidence of early, postoperative myocardial ischemia. *Ann Thorac Surg* 49:61-67, 1990
12. Philbin DM, Rosow CE, Schneider RC, Koski G, D'Ambra MN: Fentanyl and sufentanil anesthesia revisited: How much is enough. *ANESTHESIOLOGY* 73:5-11, 1990

(Accepted for publication May 20, 1992.)

Anesthesiology
77:405, 1992

Intensive Analgesia Reduces Postoperative Myocardial Ischemia? II

To the Editor:—I read with interest the recent article by Mangano and the Study of Perioperative Ischemia Research Group.¹ Their data reveal that patients who receive a continuous infusion of sufentanil after cardiac surgery have "less severe" ECG changes in the postbypass and intensive care unit time periods when compared to patients who receive intermittent intravenous injections of morphine for pain relief. From these data, the authors conclude that "the severity of ischemic episodes can be diminished following myocardial revascularization by use of prolonged intensive analgesia." Such a conclusion, while intuitively appealing, is not the only way to interpret the data.

The design of this study significantly limits any conclusions that can reasonably be drawn from its results. The two groups differ in many ways other than the degree of analgesia.

The groups received two different drugs (morphine or sufentanil). The patients in the morphine group also received significantly more midazolam. Thus, the differences in ischemia between the groups may come from a proischemic effect of morphine, not an antiischemic effect of sufentanil. The additional midazolam, alone, or in combination with the morphine, could have incited more ischemia in that group.

The intraoperative management of the groups was different. The morphine group received up to 2 mg/kg of morphine while on bypass. The sufentanil group received a bolus and infusion of sufentanil. Morphine, in these doses, has considerable hemodynamic effects. In contrast, sufentanil is well known for promoting "hemodynamic stability." Thus, differences in the intraoperative management of these two groups could be responsible for the reported results.

In the intensive care unit, the drugs were given by different protocols. In one group, the patients received intermittent injections of opioid "as needed for pain." The other group, in contrast, received a constant infusion of opioid. These different methods of drug administration could have influenced the study outcome.

Anesthesiology
77:405-406, 1992

In Reply:—We appreciate the comments of de Leon-Casasola and Lema. Regarding their suggestion that a larger study is needed, we agree and have so stated in the third limitation cited in the Discussion section. The intent of this study was to investigate the differential effects

The authors suggest that the less severe ischemia in the sufentanil group resulted from "intensive analgesia." However, they offer no data to show that the patients in the sufentanil group indeed had less pain than those in the morphine group. Admittedly, this is a difficult task when dealing with patients in whom the trachea is intubated, but I think the point is important.

Lastly, the investigation was in no way blinded. Nurses and physicians caring for the patients in the operating room and intensive care unit were most likely aware of the study. Even if they did not know the authors' hypothesis, they could have guessed it or derived one of their own. Either event might have produced subtle changes in the manner in which they responded to clinical events.

MARK C. NORRIS, M.D.
Associate Professor of Anesthesiology
Department of Anesthesiology
Jefferson Medical College
Suite G-6460
111 South 11th Street
Philadelphia, Pennsylvania 19107-5092

REFERENCE

1. Mangano DT, Siliciano D, Hollenberg M, Leung JM, Browner WS, Goehner P, Merrick S, Verrier E, SPI Research Group: Perioperative myocardial ischemia: Therapeutic trials using intensive analgesia following surgery. *ANESTHESIOLOGY* 76:342-353, 1992

(Accepted for publication May 5, 1992.)

of the techniques on the incidence and severity of perioperative myocardial ischemia. As such, the 100 patients studied provide adequate power. To differentiate the effects on myocardial infarction and cardiac death, a much larger study is needed both because of a lower incidence